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Introduction
Atherosclerotic coronary artery disease
(CAD) and its complications remain
the leading cause of death in indus-
trialized countries (Lopez et al, 2006).
In recent years, intensive lowering of
low-density lipoprotein (LDL) choles-
terol using statins has been established
as an effective therapy to lower
cardiovascular risk (Baigent et al,
2010). However, the risk of major
cardiovascular events in patients with
CAD on optimal medical therapy,
including statins, remains in the range
of 20% after 3 years of follow-up after
an acute coronary syndrome (Stone
et al, 2011). Several lines of evidence
have suggested that high-density lipoprotein (HDL) may act as
an anti-atherogenic lipoprotein, as discussed in detail in this
Review article. HDL-targeted therapies are therefore intensely
pursued as a potential novel anti-atherogenic strategy to reduce
cardiovascular risk and are an important frontier of basic,
translational and clinical cardiovascular research.
HDL cholesterol levels, atherosclerosis and
cardiovascular risk—epidemiological and
genetic studies
Initially, the concept that HDL may protect from CAD was
suggested by numerous epidemiological studies, indicating that
low plasma levels of HDL cholesterol or apoA1, the major
protein component of HDL, are associated with an increased risk
of CAD and CAD-related cardiovascular events in the general
population (Castelli et al, 1986; Di Angelantonio et al, 2009;
Gordon et al, 1977; Sharrett et al, 2001). Later studies have
suggested that also in patients with CAD and very low LDL
cholesterol levels on statin treatment, low plasma concentra-
tions of HDL cholesterol remained associated with an increased
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Low high-density lipoprotein (HDL)-cholesterol levels are associated with an
increased risk of coronary artery disease (CAD) and myocardial infarction, which
has triggered the hypothesis that HDL, in contrast to low-density lipoprotein (LDL),
acts as an anti-atherogenic lipoprotein. Moreover, experimental studies have
identified potential anti-atherogenic properties of HDL, including promotion of
macrophage cholesterol efflux and direct endothelial-protective effects of HDL,
such as stimulation of endothelial nitric oxide production and repair, anti-apoptotic,
anti-inflammatory and anti-thrombotic properties. Studies in gene-targeted mice,
however, have also indicated that increasing HDL-cholesterol plasma levels can
either limit (e.g. apolipoprotein A-I) or accelerate (e.g. Scavenger receptor class B
type I) atherosclerosis. Moreover, vascular effects of HDL have been observed to be
heterogenous and are altered in patients with CAD or diabetes, a condition that has
been termed ‘HDL dysfunction’. These alterations in biological functions of HDL may
need to be taken into account for HDL-targeted therapies and considering raising of
HDL-cholesterol levels alone is likely not sufficient in this respect. It will therefore be
important to further determine, which biological functions of HDL are critical for its
anti-atherosclerotic properties, as well as how these can be measured and targeted.
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risk of cardiovascular events (Barter et al, 2007a). Low HDL
cholesterol levels have also been suggested as a primary lipid
abnormality in patients with premature CAD (Genest et al,
1991).
However, low plasma HDL cholesterol levels may not
generally be associated with accelerated atherosclerosis. Several
studies have examined the prevalence of cardiovascular disease
in subjects with monogenic disorders of HDL metabolism, i.e.
HDL deficiency syndromes due to apolipoprotein A-I (apoA-I)
mutations, ATP binding cassette transporter A-1 (ABCA1) or
lecithin/cholesterol acyltransferase (LCAT) deficiency. As
described below, apoA-I mutations may be associated with
an accelerated development of atherosclerosis, which is less
clear for mutations in the other two genes. More recently,
genome-wide association studies (GWAS) have examined the
relation of single-nucleotide polymorphisms (SNPs) associated
with altered HDL cholesterol levels to changes in the risk of
coronary disease as described below. In addition, several
genetically modified mice have been investigated to gain further
insights into the role of HDL metabolism and function in
atherosclerotic cardiovascular disease.
Apolipoprotein A-I (apoA-I)
Apolipoprotein A-I is the main protein constituent of HDL in
plasma (Fig 1). To date, more than 40 genetic defects of apoA-I
have been described (Schaefer et al, 2010). However, the
consequences of these defects with regard to cardiovascular risk
have remained inconclusive, largely because of the limited
number of carriers of apoA-I gene defects. Notably, in one of the
larger studies involving 54 heterozygotes for the apoA-I
mutation L178P, carriers of the apoA-I gene defect had lower
plasma levels of HDL cholesterol, impaired endothelial function,
and increased carotid intima-media thickness (IMT) when
compared to non-affected family controls (Hovingh et al, 2004).
Notably, however, several apoA-I variants with amino acid
substitutions have also been associated with amyloidosis
(Schaefer et al, 2010), and amyloidosis has also been suggested
to lead to endothelial dysfunction and increased carotid IMT
(Modesto et al, 2007).
In experimental studies using atherosclerosis-susceptible
mice (inbred C57BL/6), it was observed that transgenic
overexpression of high amounts of human ApoA-I significantly
protected from development of early atherosclerotic lesions, i.e.
fatty streak lesions (Rubin et al, 1991). Similarly, overexpres-
sion of human ApoA-I in apoE-deficient mice on chow diet
suppressed early atherosclerotic lesion formation (Plump et al,
1994). Moreover, overexpression of apoA-I in mice was
associated with an increased reverse cholesterol transport
(RCT) from macrophages to feces in vivo, which might, at least
in part, account for the inhibition of atherosclerosis progression
in mice after apoA-I gene transfer (Zhang et al, 2003).
Lack of apoA-I after targeted disruption of the apoA-I gene did
not result in an increased atherosclerotic lesion formation in
mice (inbred 129-strain) on atherogenic diet, despite lower HDL
cholesterol levels (Li et al, 1993). In contrast, however,
knocking out apoA-I in human apoB-transgenic female mice,
LDL receptor-deficient and LDL receptor/apoE-deficient mice
resulted in an accelerated atherosclerosis development (Moore
et al, 2003, 2005; Voyiaziakis et al, 1998). Additional studies
evaluating the effects of apoA-I at different stages of athero-
sclerosis development in mice will be further discussed below.
ATP binding cassette transporter A-1 (ABCA1)
ABCA1 mediates efflux of cholesterol and phospholipids to
lipid-free or lipid-poor apoA-1, which leads to formation of
nascent HDL (Fig 1). Studies by several groups in 1998 identified
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Glossary
Acute coronary syndrome
A spectrum of clinical presentations ranging from ST elevation myocardial
infarction, non-ST elevation myocardial infarction to unstable angina. Any
group of symptoms compatible with a sudden interruption of the blood
flow to the heart.
Atherosclerotic coronary artery disease
Buildup of cholesterol and plaques on the inner walls of the coronary
artery. These plaques can restrict blood flow to the heart muscle by
physically clogging the artery or by causing abnormal artery tone and
function.
Carotid intima media thickness
Thickness of the inner two layers of the carotid artery—the intima and
media; a surrogate endpoint for evaluating the regression and/or
progression of atherosclerotic cardiovascular disease.
Cholesterol
A steroid metabolite found in cell membranes. It is transported in the blood
in lipoprotein particles and excess circulating cholesterol is associated with
atherosclerosis.
Endothelial cells
Cells forming the endothelium, which lines the interior surface of blood
vessels and lymphatic vessels.
Genome-wide association study (GWAS)
Examination of many common genetic variants in different individuals to
evaluate if any variant is associated with a trait. Typically single-nucleotide
polymorphisms (SNPs) are investigated and usually investigated traits
include major diseases.
High-density lipoprotein (HDL)
Good cholesterol, high levels are thought to be protective against
atherosclerosis.
Low-density lipoprotein (LDL)
Bad cholesterol, high circulating levels have been shown to correlate with
atherosclerosis.
Macrophages
Large phagocytes developed from circulating monocytes that migrate to
tissues to eliminate cellular debris and particulate antigens. They produce
and respond to inflammatory cytokines.
Nitric oxide
NO, also called nitrogen monoxide, an important cellular signalling
molecule involved in many physiological and pathological processes.
Plaque
The buildup of cells and cholesterol in the arterial wall. Severe
plaque buildup can narrow the arterial lumen interfering with the flow
of blood.
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loss-of-functionmutations in both alleles of the ABCA1 gene as a
cause of the rare Tangier´s disease that presents with extremely
low HDL cholesterol levels and tissue accumulation of
macrophages due to decreased ABCA1-mediated efflux of
cholesterol/phospholipids from peripheral cells (Rust et al,
1999). Some studies in these patients suggested an increased
risk of premature CAD (Schaefer, 1984; Schaefer et al, 2010),
however, the number of mutation carriers was very low, so that
a definitive conclusion could not be drawn. When compared to
subjects with heterozygous familial hypercholesterolemia (i.e.
very high LDL cholesterol levels caused by mutations in the LDL
receptor gene), the potential increase in cardiovascular risk in
ABCA1-deficient subjects is not as profound as expected, which
has also been ascribed to concomitantly decreased LDL
cholesterol levels in these subjects (Schaefer et al, 1980). A
recent population-based study from Denmark has demonstrated
that lower plasma levels of HDL cholesterol in subjects
heterozygous for four rare loss-of-function mutations in the
ABCA1 gene were not associated with an increased risk of
ischemic heart disease when compared to the general popula-
tion (Frikke-Schmidt et al, 2008).
Moreover, several experimental studies have examined the
effects of complete or bone-marrow-derived cell-specific
deficiency of ABCA1 (or ABCA1 and ABCG-1) on development
of atherosclerosis. Notably, complete deficiency of ABCA1 did
not result in a measurable increase of atherosclerotic lesion
formation in hypercholesterolemic apoE- or LDL receptor-
deficient mice and was associated with reduced plasma
cholesterol levels (Aiello et al, 2002). Similarly, a combined
complete deficiency of ABCA1 and the ATP binding cassette
transporter G-1 (ABCG1) had no significant effect on athero-
sclerotic lesion formation and was associated with hypocho-
lesterolemia (Out et al, 2008). In contrast, in experimental
studies in mice with a selective deficiency of ABCA1 or ABCA1/
ABCG1 in bone-marrow-derived cells (i.e. macrophages,
leukocytes) an accelerated atherosclerosis development was
observed (Aiello et al, 2002; van Eck et al, 2002). Taken
together, these findings suggest that complete absence of ABCA1
leads to marked alterations of plasma lipoprotein homeostasis,
and a potential atherogenic effect from ABCA1 deficiency may
be compensated for by a less atherogenic lipoprotein profile. In
contrast, deletion of ABCA1 or both ABCA1 and ABCG1 only in
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Figure 1. Molecular biosynthesis of HDL. Lipid-free apoA-I is secreted by the liver and intestine and acquires phospholipids and free cholesterol via hepatic
and intestinal ABCA-1. Nascent HDL takes up further phospholipids (via PLTP) as well as free cholesterol from peripheral tissues and triglyceride-rich lipoproteins.
HDL-associated LCAT esterifies part of the free cholesterol to cholesterol esters, thereby forming the hydrophobic core of the HDL particle (‘HDL maturation’).
HDL-associated cholesterol is either directly transferred to the liver via hepatic SR-BI or following CETP-mediated transfer to VLDL/LDL via the hepatic LDL
receptor.
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bone-marrow-derived cells (macrophages, leukocytes) led to an
accelerated atherosclerotic lesion formation, suggesting that the
transporter activity in bone marrow-derived cells (macro-
phages, leukocytes) exerts an anti-atherogenic effect that is
particularly visible when both transporters, i.e. ABCA1 and
ABCG1, are deleted (Yvan-Charvet et al, 2007).
The findings regarding the effect of ABCA1 overexpression on
atherosclerosis development in mice are not entirely consistent,
and there are likely important differences between systemic and
hepatic overexpression of ABCA1. Human ABCA1-transgenic
mice (overexpressing ABCA1 in multiple tissues) on an apoE-
deficient background developed smaller and less complex
atherosclerotic lesions compared to control mice (Singaraja
et al, 2002). Increasing ABCA1 levels using anti-miR-33
treatment has recently been observed to reduce atherosclerotic
plaque size and lipid content in LDL receptor-deficient mice
(Rayner et al, 2011). On the contrary, however, ABCA1
overexpression in the liver of LDL receptor-deficient mice
resulted in a pro-atherogenic lipoprotein profile and increased
atherosclerotic lesion formation (Joyce et al, 2006). Moreover,
hepatocyte-specific overexpression of murine ABCA1 in apoE-
deficient mice has been shown to increase HDL cholesterol
levels in plasma, but accelerated atherosclerosis development in
these mice (Feng et al, 2010). HDL isolated from apoE-deficient
mice overexpressing ABCA1 failed to stimulate migration of
endothelial progenitor cells and to inhibit endothelial cell
apoptosis in vitro (Feng et al, 2010). Interestingly, Yamamoto
et al have recently reported that pharmacological inhibition of
hepatic ABCA1 activity leads to reduced HDL cholesterol plasma
levels and is associated with an augmented RCT in the bile,
suggesting that hepatic inhibition of ABCA1 may promote
reverse cholesterol transport (Yamamoto et al, 2011). Taken
together, these findings suggest that increasing ABCA1 expres-
sion/activity systemically may exert anti-atherogenic effects,
whereas a selective overexpression of ABCA1 in the liver may
result in an accelerated development of atherosclerosis.
Lecithin/cholesterol acyltransferase (LCAT)
Lecithin/cholesterol acyltransferase mediates the conversion of
free cholesterol into cholesteryl ester in HDL and thereby plays a
role in the maturation of the HDL particle (Fig 1). The findings
on carotid atherosclerosis in LCAT-deficient patients are
heterogenous and may result from population differences.
Hoving et al suggested that carriers of LCAT gene mutations
have increased carotid IMT as assessed by B-mode ultrasound
(Hovingh et al, 2005). In a study by Calabresi et al, subjects with
low HDL cholesterol levels due to one or two loss-of-function
mutations in the LCAT gene did not show an increased carotid
IMT when compared to matched healthy subjects as examined
by carotid ultrasound (Calabresi et al, 2009a). Similarly, there
was no association between plasma LCAT concentration and
carotid IMT observed by this group in subjects with a high-risk
acute coronary syndrome that were not yet on drug treatment,
indicating that LCAT deficiency may not increase the risk of
carotid atherosclerosis (Calabresi et al, 2011). Moreover, it has
been suggested that LCAT activity is not required for the ability
of human plasma to promote macrophage cholesterol efflux
in vitro (Calabresi et al, 2009b) and may have a minor role for
transport of cholesterol frommacrophages to the liver in human
apoA-I transgenic mice (Tanigawa et al, 2009), which is
consistent with the observation that HDL directly transfers a
large amount of unesterified cholesterol to the liver for biliary
cholesterol excretion (Schwartz et al, 1978, 1982). However, a
more recent study using 3.0-T magnetic resonance imaging
observed that carriers of LCAT gene mutations with decreased
HDL cholesterol levels exhibited an increased carotid athero-
sclerosis (Duivenvoorden et al, 2011).
Scavenger receptor class B type I (SR-BI)
Hepatic SR-BI mediates the selective uptake of HDL cholesterol
by the liver and is therefore considered a key receptor for HDL
cholesterol clearance from plasma (Fig 1). Furthermore,
endothelial SR-BI has been shown to mediate potentially
important atheroprotective signalling in endothelial cells
induced by HDL (see sections below). Overexpression of
hepatic SR-BI increased transport of cholesterol from macro-
phages to the liver and its secretion into the bile in mice,
although plasma levels of HDL cholesterol were reduced (Zhang
et al, 2005). Conversely, SR-BI-deficient mice have increased
HDL cholesterol levels, but increased atherosclerosis (Huby
et al, 2006), suggesting that SR-BI expression is inversely related
to plasma levels of HDL cholesterol and development of
atherosclerosis.
Recently, Vergeer et al identified a novel missense mutation
(P279S) of SR-BI in a Dutch family with markedly elevated
plasma concentrations of HDL (i.e. above the 95th percentile of
normal; Vergeer et al, 2011). Adenoviral expression of the P279S
variant in SR-BI-deficient mice led to a reduction of the
cholesterol ester uptake capacity of hepatocytes in these mice
when compared to wild-type SR-BI, and the cholesterol efflux
from monocyte–macrophages obtained from carriers of the
P279S variant was lower, as compared to noncarriers (Vergeer
et al, 2011).
The above findings further support the concept that HDL
cholesterol plasma levels should not be considered in isolation
as a therapeutic target or read-out for the capacity of
macrophage RCT, since lower HDL cholesterol levels can also
be associated with an enhanced RCT capacity (as described
above) and higher HDL cholesterol levels after SR-BI knockout
can be associated with accelerated atherosclerosis.
Genome-wide association studies (GWAS)
Recently, GWAS have emerged as a novel tool to identify
common genetic variants that are associated with changes in
blood lipids (Teslovich et al, 2010). In these studies, it can be
determined whether SNPs associated with altered lipid levels
are also associated with altered risk of CAD. Notably and in
striking contrast to several SNPs associated with higher LDL
cholesterol serum levels that were uniformly associated with
increased risk of CAD, the findings for SNPs associated with
increased HDL cholesterol levels revealed no clear association
with CAD risk (Willer et al, 2008). Some SNPs associated with
higher HDL cholesterol tended to be associated with an
increased and others tended to be associated with a decreased
Review
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risk of CAD (Willer et al, 2008). Interestingly, the above
observations in gene-targeted mice suggest that increased HDL
cholesterol levels may be indicative of a potential protective
mechanism (i.e. increased apoA-I levels) or may reflect an
alteration of an HDL-related pathway that may lead to potential
pro-atherosclerotic effects (i.e. SR-BI mutation). Together, these
studies further indicate that plasma concentrations of HDL
cholesterol alone are likely not a sufficient marker to determine
potential anti-atherogenic effects of HDL, an observation that is
highly relevant for the design and evaluation of HDL-targeted
therapies.
In a more recent GWAS, several loci were identified that were
specifically related to HDL cholesterol or triglycerides, but not
LDL cholesterol, and were associated with the risk of CAD
(Teslovich et al, 2010). These findings support the concept that
it is possible to modulate HDL cholesterol in a way congruently
with a reduced risk of CAD, however, these studies cannot yet
prove that the change in HDL cholesterol is causal for the change
in CAD risk.
Biosynthesis of HDL
Secretion and initial lipidation of apoA-I
The first step of the biosynthesis of HDL entails the synthesis
and secretion of apoA-I, the major protein constituent of HDL,
by the liver and intestine (Rader, 2006). The second most
abundant HDL protein, apoA-II, is synthesized only in the liver
and its secretion results in the formation of a subclass of HDL
particles containing apoA-I and apoA-II (Tailleux et al, 2002).
Following secretion in the liver and intestine, lipid-poor
apoA-I immediately acquires cholesterol and phospholipids, in
particular from hepatocytes and enterocytes (Brunham et al,
2006; Timmins et al, 2005). The initial lipidation of apoA-I is
primarily mediated by ABCA-1 and results in the formation of
nascent HDL (Fig 1). Nascent HDL acquires additional
phospholipids and free cholesterol from extrahepatic tissues.
The relative contribution of different organs for extrahepatic
lipidation of HDL remains largely unknown. However, trans-
plantation of bone marrow from wild-type mice into ABCA-1-
deficient mice resulted only in a very modest increase in HDL
cholesterol levels, suggesting that macrophages are likely not a
major source of HDL cholesterol mass in mice (Haghpassand
et al, 2001).
Phospholipidation of HDL
In addition, HDL acquires phospholipids and potentially
apolipoproteins (such as apoC-III) during hydrolysis of
triglyceride-rich lipoproteins (Fig 1). The transfer of phospho-
lipid surface remnants from trigylceride-rich lipoproteins to
HDL is mediated via the phospholipid transfer protein (PLTP)
(Masson et al, 2009). Phospholipids transferred via PLTP are not
only an important structural component of the HDL surface, but
also serve as substrate for the esterification of HDL-associated
cholesterol. Moreover, PLTP promotes the fusion of smaller
HDL3 particles and subsequent generation of larger HDL2
particles (a process termed ‘HDL conversion’; Lagor & Rader,
2011). During this process, lipid-poor apoA-I is shed off and can
again undergo lipidation for regeneration of preb-HDL. In
transgenic animal models, increased systemic levels of PLTP
have been shown to promote atherosclerosis in mice (van
Haperen et al, 2002; Yang et al, 2003) and rabbits (Masson et al,
2011). PLTP deficiency in atherosclerosis-prone mice results in
decreased atherosclerotic plaque formation (Jiang et al, 2001).
These findings have been attributed, at least in part, to changes
in apolipoprotein B (apoB) production and plasma cholesterol
levels in these animals, since PLTP also stimulates hepatic
secretion of VLDL, possibly by phospholipidation of nascent
apoB (Lie et al, 2002).
Studies on the association of PLTP activity and cardiovascular
risk in humans have been complicated by the fact that PLTP
activity and PLTP mass are affected by various cardiovascular
risk factors, and poorly correlate with each other (Lagor &
Rader, 2011). Interestingly, a recent study demonstrated
that two SNPs at the PLTP locus that showed decreased
PLTP mass and activity were strongly associated with a lower
risk of cardiovascular disease, despite reduced plasma con-
centrations of HDL (Vergeer et al, 2010). Notably, in this study
there was no association between the SNPs at the PLTP locus
and plasma concentrations of LDL, suggesting an apoB-
independent effect. In a smaller case control study, four SNPs
in the PLTP locus were shown to be associated with the presence
of carotid atherosclerosis (Jarvik et al, 2010). Among these,
individuals with the rs6065904 allele showed elevated PLTP
activity and this was associated with increased carotid
atherosclerosis.
These studies suggest that decreased PLTP activity due to
genetic variants at the PLTP locus are associated with a reduced
cardiovascular risk in humans, indicating that increased
phospholipidation of HDL does not necessarily lead to
cardiovascular risk reduction, although it may raise HDL
cholesterol levels.
Esterification of HDL-associated cholesterol by LCAT
Following efflux of cholesterol and phospholipid transfer from
peripheral tissues, a proportion of HDL-associated free choles-
terol in plasma is esterified to cholesteryl ester by LCAT (Fig 1).
Although LCAT activity results in the formation of a hydrophic
core in HDL and thus is important for maturation of the HDL
particle, recent studies in subjects with LCAT mutations and
LCAT-transgenic mice have suggested that LCAT likely does not
play a major role for efficient transport of cholesterol from
peripheral tissues back to the liver (Rader, 2009). As described
above, the findings with respect to the vascular phenotype of
subjects with LCAT mutations are heterogenous.
HDL cholesterol uptake by the liver
Hepatic SR-BI can selectively take up cholesteryl ester and
unesterified cholesterol and thus directly deliver HDL-asso-
ciated cholesterol to the liver (Cuchel & Rader, 2006; Ji et al,
1999). Alternatively, in humans and some other species, HDL
cholesterol can be transferred to apoB-containing lipoproteins
in exchange for triglycerides via the cholesteryl ester
transfer protein (CETP) and subsequently be cleared by LDL
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receptor-mediated uptake of apoB-containing lipoproteins to the
liver (Fig 1). In transgenic mice (that normally lack CETP) with
CETP gene transfer, the transport of cholesterol from macro-
phages to the liver was increased (Tanigawa et al, 2007).
However, studies on the effect of CETP on development of
atherosclerosis in mice have yielded mixed results. Whereas
overexpression of CETP increased atherosclerosis in wild-type
and hypercholesterolemic mouse models (de Vries-van der Weij
et al, 2009; Plump et al, 1999), a decreased atherosclerotic
plaque burden was observed in CETP transgenic hypertrigly-
ceridemic mice and in CETP transgenic mice overexpressing
LCAT, despite lower plasma HDL cholesterol levels in these
animals (Foger et al, 1999; Hayek et al, 1995). In rabbits (that are
expressing CETP), inhibition of CETP by JTT-705 (today called
dalcetrapib) attenuated atherosclerosis (Okamoto et al, 2000).
Because CETP inhibition may change the composition of HDL
particles and give rise to large HDL particles enriched in
cholesterol esters, another study sought to characterize the
ability of HDL from CETP-deficient subjects to mediate
cholesterol efflux from macrophage foam cells (Matsuura
et al, 2006). However, the cholesterol efflux potential of HDL
isolated from human subjects with homozygous CETP defi-
ciency was rather increased compared to normolipidemic
control subjects. Importantly, whether pharmacological CETP
inhibition by different CETP inhibitors affects other anti-
atherogenic properties of HDL in patients with CAD remains
to be tested in future studies.
Molecular mechanisms mediating potential
atheroprotective functions of HDL:
alterations in cardiovascular disease
In recent years, several properties or functions of HDL have been
identified that could exert anti-atherosclerotic effects. Besides
promoting macrophage cholesterol efflux and RCT, HDL has
more recently been shown to exert direct potentially anti-
atherosclerotic effects on endothelial cells, such as the direct
stimulation of endothelial nitric oxide production by HDL or
endothelial anti-inflammatory effects and anti-oxidant effects
that will be discussed in more detail below (Fig 2). Notably,
however, recent evidence suggests that vascular effects of HDL
can be highly heterogeneous and are altered in patients with
cardiovascular disease.
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Figure 2. Proposed anti-atherogenic effects of HDL in the endothelium. Besides stimulation of macrophage cholesterol transport, HDL has been shown to
inhibit endothelial inflammatory activation and to promote endothelial repair. Both effects have been observed to be dependent on endothelial NO production.
Furthermore, HDL exerts anti-apoptotic and anti-thrombotic effects that may contribute to its anti-atherogenic capacity.
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Reverse cholesterol transport
Physiological mechanisms
Early on, potential anti-atherogenic effects of HDL were mainly
attributed to its function in macrophage RCT, i.e. the removal of
excess cholesterol from lipid-ladenmacrophage foam cells in the
atherosclerotic plaque and its transport to the liver for excretion
in the bile (Rader, 2006; Ross & Glomset, 1973).
Hydrolysis of cytoplasmatic cholesteryl esters to free
cholesterol and the subsequent efflux of the free cholsterol to
mature HDL or extracellular lipid-poor apoA-I is the first step of
macrophage RCT. While it was initially thought that efflux of
cholesterol from macrophages was primarily mediated by
passive diffusion (Glomset, 1968), it has become clear that
macrophage cholesterol efflux is facilitated by active transport
systems, including the ABCA1 and ATP binding cassette
transporter G1 (ABCG1) transporters (Rader, 2006; Tall et al,
2008). ABCA-1 primarily mediates the cholesterol efflux to lipid-
poor apoA-I as studies in macrophages from ABCA1-knockout
or -overexpressing mice have indicated (Bortnick et al, 2000;
Haghpassand et al, 2001; Van Eck et al, 2006). In contrast,
ABCG1 largely mediates cholesterol efflux from macrophages to
mature HDL (Tall et al, 2008).
Interestingly, a recent study has quantitatively assessed the
roles of SR-BI, ABCA1 andABCG1 inmacrophage RCT inmice in
vivo (Wang et al, 2007). Using primary macrophages lacking SR-
BI, the authors demonstrated that SR-BI did not promote
macrophage RCT in vivo after intraperitoneal injection. In
contrast, ABCA1 and ABCG1 contributed in an additive fashion
to stimulation of macrophage RCT in vivo, and transplantation
of bonemarrow fromABCA1/ABCG1-deficient mice accelerated
atherosclerotic lesion formation in LDL receptor-deficient mice
(Wang et al, 2007). Consistently, Yvan-Charvet et al (Yvan-
Charvet et al, 2008) demonstrated that SR-BI failed to stimulate
net cholesterol efflux from HEK293 cells to plasma HDL and
inhibited ABCG1-mediated cholesterol efflux, which was at least
in part due to an increased uptake of HDL cholesteryl esters into
these cells.
Following efflux from macrophages, HDL-associated choles-
terol can get esterified by LCAT that transfers a fatty acyl residue
from phospholipids to the 3-beta-hydroxy group of cholesterol
(Rader, 2009). The final steps of RCT include the uptake of HDL
cholesterol by the liver and its excretion in the bile. As described
above, cholesterol esters and free cholesterol in HDL can either be
directly taken up by the liver via SR-BI or transferred to apoB-
containing lipoproteins in a process mediated by CETP (Cuchel &
Rader, 2006). In the latter pathway, cholesterol esters are taken
up by the liver via the LDL receptor. Hepatic cholesterol esters are
then hydrolysed to free cholesterol that can be excreted into the
bile either directly or following conversion to bile acid.
Alterations in cardiovascular disease
Of note, a recent study indicated that the cholesterol efflux
capacity of apoB-depleted serum (as ameasure of the capacity of
HDL to accept cholesterol from macrophages) was inversely
related to carotid IMT in healthy volunteers and to the likelihood
of angiographic CAD in a case-control study (Khera et al, 2011).
Importantly, these associations persisted after adjustment for
HDL cholesterol and apoA-I levels. A reduced cholesterol efflux
capacity via SR-BI- and ABCG-1-dependent pathways was also
observed for large HDL2 particles in patients with familial
hypercholesterolemia (Bellanger et al, 2011). Furthermore, the
ability of HDL to deliver cholesterol esters to the liver was
impaired in these patients, as detected using an in vitro model
with HepG2 cells. However, a critical open question remains
whether macrophage cholesterol efflux capacity, or any other
atheroprotective function of HDL, is associated with clinical
cardiovascular disease progression and outcome.
Stimulation of endothelial cell nitric oxide (NO) production
Physiological mechanisms
In recent years it has become clear that HDL from healthy
subjects can exert direct potential atheroprotective effects on
endothelial cells and the understanding of the vascular effects of
HDL considerably changed with the important observation
that HDL may directly stimulate endothelial NO synthase-
mediated NO production as well as induce endothelium-
dependent, NO-mediated vasodilation via endothelial SR-BI
(Yuhanna et al, 2001). Endothelial NO plays a crucial role in the
regulation of vascular tone and structure (Landmesser et al,
2004), and, importantly, endothelial NO has been shown to
exert a variety of atheroprotective effects in the vasculature,
such as anti-thrombotic, anti-coagulant, anti-inflammatory and
pro-fibrinolytic effects.
In addition, experimental studies have consistently demon-
strated the capacity of HDL tomodify eNOS expression aswell as
activity and to stimulate endothelial NO production in vitro and
in vivo (Besler et al, 2011; Kuvin et al, 2002; Mineo et al, 2003;
Nofer et al, 2004; Ramet et al, 2003; Sorrentino et al, 2010).
Moreover, in humans, administration of reconstituted HDL has
been shown to improve endothelial function in subjects with
hypercholesterolemia and in subjects with isolated lowHDL due
to heterozygous loss-of-function mutations in the ABCA-1 gene
locus (Bisoendial et al, 2003; Spieker et al, 2002).
Several different mechanisms have been proposed to account
for the endothelial NO-stimulating capacity of HDL (Fig 3). Early
studies have suggested that HDL acts by preventing the
detrimental effects of oxidized LDL on endothelial NO-synthase
(Uittenbogaard et al, 2000) while a subsequent study by
Yuhanna et al (Yuhanna et al, 2001) suggested that HDL can
bind to endothelial SR-BI and thus directly stimulate eNOS-
mediated NO production. Mechanistically, binding of HDL to
SR-BI initially leads to tyrosine kinase Src-mediated activation of
phosphoinositide (PI) 3-kinase, which in turn activates Akt and
the MAP kinase/extracellular signal-regulated kinase pathway
(Mineo et al, 2003). This activation of endothelial Akt has been
shown to stimulate phosphorylation of eNOS at serine residue
1177 (Mineo et al, 2003; Nofer et al, 2004), known to be an
important regulatory mechanism leading to eNOS activation
(Dimmeler et al, 1999). In contrast, the mechanism through
which the MAP kinase/extracellular signal-regulated kinase
pathway activates eNOS in endothelial cells stimulated with
HDL remains to be further elucidated.
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However, other HDL components besides apoA-I are likely
to be important for the eNOS-stimulating capacity of HDL
since isolated apoA-I, the major SR-BI ligand of HDL, failed to
activate eNOS in these studies. Interestingly, stimulation
of eNOS-mediated NO production is also induced by binding
of HDL-associated lysophospholipids (i.e. sphingosylphos-
phorylcholine, sphingosine-1-phosphate, lysosulfatide) to the
lysophospholipid receptor S1P3 (Fig 3) that is expressed in
endothelial cells and may partially mediate HDL- and lysopho-
spholipid-induced vasodilation (Nofer et al, 2004). In this
respect, an interaction between S1P3 and SR-BI to induce HDL
signalling in endothelial cells has been suggested in which
binding of HDL with SR-BI could provide the necessary spatial
proximity for lysophospholipids to effectively stimulate S1P3
(Nofer et al, 2004).
Recently, Terasaka et al (Terasaka et al, 2008) identified a
novel mechanism whereby HDL may maintain endothelial cell
NO production and availability in mice fed a high-cholesterol
diet. These authors suggested that ABCG1-mediated efflux of
oxysterols from endothelial cells plays a role since 7-ketosterol,
a dietary oxysterol, accumulated in endothelial cells of ABCG1-
deficient mice on a western diet (Terasaka et al, 2008).
Interestingly, incubation of human aortic endothelial cells with
HDL prevented 7-ketosterol-induced production of reactive
oxygen species and disruption of the active eNOS dimer.
Furthermore, HDL-mediated cholesterol efflux via ABCG-1
reduced the inhibitory interaction of eNOS with caveolin-1
and thereby restored eNOS activity in cholesterol-loaded
endothelial cells (Terasaka et al, 2010). These data suggest
that the ability of HDL to preserve endothelial function in the
presence of hypercholesterolemia may, at least in part, relate to
an increased endothelial efflux of oxysterols (Fig 3).
Notably, a recent study from our group has identified the
HDL-associated antioxidant enzyme paraoxonase (PON) 1 as an
important determinant of the capacity of HDL to stimulate
endothelial NO production and to exert NO-dependent endothe-
lial-atheroprotective effects (Besler et al, 2011). Inhibition of
PON1 in HDL from healthy subjects impaired the capacity of
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Figure 3. Signalling pathways mediating the effects of HDL on endothelial NO production. HDL has been shown to stimulate endothelial NO synthase
phosphorylation at serine residue 1177 via binding of apoA-I to SR-BI and binding of HDL-associated lysophospholipids to the S1P3 receptor. In addition, HDL-
mediated efflux of 7-oxysterols via endothelial ABCG-1 has been observed to inhibit the interaction between eNOS and caveolin, and to prevent the loss of eNOS
dimerization induced by reactive oxygen species in the endothelium.
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HDL to stimulate endothelial NO production and HDL isolated
from PON1-deficient mice failed to stimulate NO production in
mouse aortic endothelial cells. Furthermore, inhibition of eNOS-
mediated NO production prevented the inhibitory effects of HDL
from healthy subjects on nuclear factor kB (NF-kB) activity,
vascular cell adhesion molecule (VCAM)-1 expression and
endothelial monocyte adhesion, suggesting that the capacity of
HDL to stimulate endothelial NO production is important
for these endothelial anti-inflammatory effects of HDL (Besler
et al, 2011).
Alterations in cardiovascular disease
We and others have recently shown that the direct endothelial
effects of HDL from patients with CAD and diabetes are
markedly altered when compared to HDL from healthy subjects.
In marked contrast to HDL from healthy subjects, HDL from
patients with diabetes and low levels of HDL cholesterol failed to
stimulate endothelial cell NO production and to promote
endothelial repair in a carotid artery injury model in mice
(Sorrentino et al, 2010). Moreover, HDL from patients with
either stable CAD or an acute coronary syndrome—in contrast
to HDL from age- and gender-matched healthy subjects—
inhibited rather than stimulated endothelial cell NO production
and lost the capacity to limit endothelial inflammatory
activation as well as to promote endothelial repair in vivo
(Besler et al, 2011).
Inhibition of lipid oxidation by HDL
Basic mechanisms
In the initiation and progression of atherosclerotic vascular
disease, accumulation and subsequent oxidation of LDL in the
subendothelial space is thought to play an important role.
Oxidized LDL, a pro-atherogenic form of LDL, is taken up by
scavenger receptors of macrophages and several studies
have demonstrated that oxidatively modified LDL promotes
endothelial cell inflammatory activation (Navab et al, 2004).
Modification of LDL by 1-electron oxidants, such as tyrosyl
radical or nitrogen dioxide radical, leads to the formation of lipid
hydroperoxides and advanced products of oxidation, i.e.
alkanes, aldehydes and isoprostanes. Of note, it has been
suggested that HDL is major carrier of both early and late
products of lipid oxidation (Bowry et al, 1992; Proudfoot et al,
2009) and that apoA-I, the main protein constituent of HDL, is
capable of binding and removing lipid hydroperoxides of LDL
in vitro and after injection into mice as well as after infusion
in humans in vivo (Navab et al, 2000). In addition, HDL
contains several anti-oxidant enzymes that may be involved
in prevention of lipid oxidation or degradation of lipid
hydroperoxides, such as LCAT, platelet-activating factor
acetylhydrolase (PAF-AH), reduced glutathione selenoperox-
idase and PON1. In particular, mice deficient in PON1
displayed significantly larger aortic atherosclerotic lesions
as compared to their wild type controls and HDL isolated
from PON1-deficient mice was unable to prevent LDL
oxidation in a cell co-culture model of the arterial wall (Shih
et al, 1998).
However, others have questioned the hypothesis that HDL
directly acquires lipid hydroperoxides from LDL or is oxidized in
plasma, since the transfer of lipid hydroperoxides between LDL
and HDL appears to be slow and the plasma contains several
anti-oxidant defense mechanisms (Shao & Heinecke, 2009).
Another explanation for the enrichment of lipid hydroperoxides
in HDL could be the fact that HDL binds lipid oxidation products,
such as 7-ketocholesterol (Terasaka et al, 2008) at sites of
inflammation and transports them back to the plasma, thereby
protecting endothelial cells against inflammatory activation
(Shao & Heinecke, 2009). Of interest in this respect, Nicholls and
colleagues (Nicholls et al, 2005) have reported that reconstituted
HDL inhibits superoxide production and vascular inflammation
induced by a non-occlusive carotid periarterial collar in
normocholesterolemic rabbits.
Alterations of antioxidant effects of HDL in acute phase response
and cardiovascular disease
In 1995, Van Lenten et al demonstrated that HDL obtained
during an acute phase response (i.e. within 2–3 days after
cardiac surgery) promoted rather than inhibited LDL-induced
endothelial monocyte chemoattractant protein (MCP)-1 expres-
sion and monocyte adhesion, indicating that the anti-inflam-
matory properties of HDL can be highly heterogenous (Van
Lenten et al, 1995). The capacity of HDL to inhibit oxidative LDL
modification induced in a reconstituted artery wall model (i.e. a
coculture of smoothmuscle and endothelial cells) was markedly
impaired during the acute phase response. Similarly, an acute
Influenza A infection in wild type mice progressively impaired
the ability of HDL to inhibit LDL oxidation and LDL-induced
monocyte chemotactic activity in human artery wall cell
cocultures up to 9 days after inoculation (Van Lenten et al,
2001).
More recent studies addressed the question whether HDL also
has altered effects on LDL oxidation in patients with
cardiovascular disease. In marked contrast to the anti-oxidative
and anti-inflammatory effects of HDL from healthy subjects,
HDL from normolipidemic patients with angiographically
confirmed CAD (i.e. ‡50% narrowing of at least one coronary
artery) increased LDL-induced monocyte chemotactic activity
by human artery wall cells and promoted LDL oxidation (Navab
et al, 2001). A subsequent study by Ansell et al suggested that
the capacity of HDL to alter LDL-induced monocyte chemotactic
activity in patients with CAD was somewhat improved after
6 weeks of simvastatin therapy (Ansell et al, 2003). However,
HDL from patients with CAD on statin therapy remained pro-
inflammatory in contrast to HDL from age- and sex-matched
healthy subjects.
Other potential anti-atherogenic properties of HDL
HDL isolated from healthy subjects or reconstituted HDL
has also been shown to stimulate endothelial repair
mechanisms and to inhibit endothelial cell apoptosis, platelet
aggregation and expression of prothrombotic factors in
endothelial cells, that may contribute to anti-atherogenic
properties of HDL (Barter et al, 2004; Mineo et al, 2006; Mineo
& Shaul, 2007).
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Effects of HDL on development and progression
of atherosclerosis
Animal models of atherosclerosis
Important in vivo evidence demonstrating that HDL might
protect against development and progression of atherosclerosis
came from studies in cholesterol-fed rabbits. Badimon et al
(Badimon et al, 1989) observed that administration of homo-
logous HDL plasma fractions concomitantly with an atherogenic
diet inhibited aortic fatty streak formation and cholesterol
deposition in cholesterol-fed rabbits. Furthermore, in choles-
terol-fed rabbits with pre-existing atherosclerosis administra-
tion of homologous HDL plasma fractions induced regression of
established aortic fatty streaks and lipid deposits (Badimon et al,
1990). Similarly, liver-directed gene transfer of human apoA-I in
LDL-receptor-deficient mice with pre-existing atherosclerotic
lesions (induced by 5 weeks of western-type diet) led to
regression of atherosclerotic lesion area (Tangirala et al, 1999).
However, subsequent studies have questioned whether a
selective increase of HDL can induce regression of athero-
sclerotic lesions as described below.
Transplantation of thoracic aortic segments from apoE-
deficient mice containing advanced atherosclerotic lesions into
syngeneic apoE-deficient mice expressing a human apoA-I
transgene retarded progression of atherosclerosis and remo-
delled atherosclerotic plaques towards a more stable appearing
phenotype (Rong et al, 2001). Likewise, adenoviral apoA-I
transfer into LDL-receptor-deficient mice with pre-existing
atherosclerotic lesions increased collagen content in lesions,
but did not induce regression (Van Craeyveld et al, 2011).
Furthermore, hepatocyte-directed adenoviral rabbit apoA-I or
rabbit LCAT transfer inhibited progression of atherosclerosis
and induced cholesterol unloading of pre-existing atherosclero-
tic plaques in LDL-receptor-deficient rabbits (Van Craeyveld
et al, 2009). These findings suggest that HDL may induce
regression of atherosclerosis only in early atherosclerotic lesions
and not in advanced atherosclerotic lesions. However, HDLmay
lead to ‘remodelling’ of advanced atherosclerotic lesions as
described above (Rong et al, 2001).
More recently, studies have examined the effect of recombi-
nant apoA-I Milano/phospholipid complexes (also known as
ETC-216) on development and progression of atherosclerosis in
animal models. ApoA-IMilano is a naturally occurring variant of
the major HDL protein apoA-I containing an arginine to cysteine
substitution at amino acid 173. Infusion of recombinant apoA-I
Milano reduced neointima formation after arterial injury in
cholesterol-fed rabbits (Ameli et al, 1994) and prevented aortic
atherosclerosis in apoE-deficient mice on a high-cholesterol diet
(Shah et al, 1998). Notably, in these studies the prevention of
neointimal thickening or atherosclerosis progression was
accompanied by a decreased lipid and macrophage content in
the arterial wall.
Human atherosclerosis
Given the above discussed results of recombinant apoA-I
Milano/phospholipid complexes in animal models of experi-
mental atherosclerosis, Nissen and colleagues (Nissen et al,
2003) conducted a prospective randomized placebo-controlled
clinical trial that investigated the effect of 5 weekly infusions of
two doses of recombinant apoA-I Milano/phospholipid com-
plexes or placebo on coronary atheroma burden as measured by
intravascular ultrasound (IVUS) in patients with an acute
coronary syndrome. This study suggested that infusion of
recombinant apoA-I Milano/phospholipid complexes results in
a small, but significant regression of coronary atheroma volume
as compared with no significant change from baseline in the
placebo group. Forty-seven patients were included in the
analysis. However, the dose of apoA-I Milano that was infused
during the trial was high, making it an expensive treatment that
is difficult to translate into the clinical setting. In one patient the
treatment was terminated due to a possible hypersensitivity
reaction (Nissen et al, 2003).
Notably, a second study characterized the effects of 4 weekly
infusions of reconstituted HDL (CSL-111, i.e. apoA-I and
phosphatidylcholine, 40 or 80mg/kg) or placebo on coronary
atheroma burden in 183 patients with a recent acute coronary
syndrome (Tardif et al, 2007). The higher-dosage CSL-111
treatment group was discontinued early because of liver
function test abnormalities. Two to three weeks after the
last infusion, there was no significant difference in atheroma
volume (% change in atheroma volume: 3.4% with CSL-111
and 1.6% with placebo) or nominal change in plaque
volume between the low-dose CSL-111 and placebo group
as assessed by IVUS. However, infusion of CSL-111
significantly improved the plaque characterization index, a
secondary endpoint, on IVUS and coronary score on quantita-
tive coronary angiography.
Additional larger studies using infusions of different forms of
reconstituted HDL are currently under way and will shed more
light into the potential effects of such an administration of HDL
on coronary atherosclerosis.
Potential HDL-targeted therapies
HDL-targeted therapies are currently intensely evaluated as a
potential novel treatment strategy to address the substantial
residual risk in patients with atherosclerotic cardiovascular
disease. Degoma and Rader have recently classified HDL-
targeted drugs that are currently tested in preclinical or clinical
studies into four groups (Degoma & Rader, 2011): drugs which
are (i) directly augmenting apoA-I levels (apoA-I infusions,
upregulators of endogenous apo A-I production), (ii) indirectly
augmenting apoA-I and HDL cholesterol levels (CETP inhibitors,
niacin, endothelial lipase inhibitors), (iii) mimicking the
functionality of apoA-I (i.e. apoA-I mimetics) and (iv) enhancing
RCT (liver receptor agonists, LCAT activators). Most of these
HDL-targeted drugs are still in preclinical or early clinical
investigation. In the search for an HDL-raising, cardioprotective
drug recent interest has primarily focused on niacin and CETP
inhibitors, and the present reviewwill provide a short update on
recent clinical trials testing these compounds.
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Niacin
Niacin (nicotinic acid) has been shown to increase HDL
cholesterol levels dose-dependently by 15–35% and lowers
plasma concentrations of other potential pro-atherogenic
lipoproteins, i.e. LDL cholesterol, trigylcerides and lipoprotein
(a) (Gille et al, 2008).
A recent experimental study in rabbits indicated that the
effects of niacin on endothelial function and vascular inflam-
mation are, at least in part, independent of changes in plasma
lipid levels (Wu et al, 2010). Moreover, Lukasova et al have
recently reported that niacin can reduce the progression of
atherosclerosis in mice independently of its lipid-modifying
effects through the activation of GPR109A on immune cells
(Lukasova et al, 2011). We have observed that extended-release
niacin treatment improved endothelial-protective functions of
HDL in type 2 diabetics with low HDL-cholesterol levels
(Sorrentino et al, 2010).
In the Coronary Drug Project (CDP), niacin reduced the rates
of myocardial infarction during the initial 5-years follow-up
compared to placebo; however, there was no significant
difference in the primary endpoint of the rate of death from
any cause between the niacin and placebo group (The Coronary
Drug Project Research Group, 1975). However, after 15 years of
follow-up there was a significant reduction in all-cause mortality
in the group that was initially randomised to niacin therapy
(Canner et al, 1986), but these results have to be interpretedwith
caution since the randomised treatment duration was limited to
8 years.
In the HDL-Atherosclerosis Treatment Study (HATS), com-
bination therapy with niacin and simvastatin slowed progres-
sion of coronary atherosclerosis and the occurrence rate of a first
cardiovascular event in patients with CAD and low HDL-
cholesterol levels (Brown et al, 2001). However, in this study the
number of patients was limited and there was no simvastatin
monotherapy group.
The Arterial Biology for the Investigation of the Treatment
Effects of Reducing Cholesterol (ARBITER) studies 2, 3 and 6
evaluated the effects of niacin on carotid atherosclerosis in
patients with CAD (or CAD risk equivalent) on statin therapy. In
ARBITER-2, extended release-niacin reduced carotid intima
media thickness (cIMT) in these patients after 1 year of follow-
up, but there was no significant difference compared to the
placebo group (Taylor et al, 2004). The follow-on open label
uncontrolled crossover study, ARBITER-3, reported a significant
regression of cIMT after further 12 months on extended release-
niacin (Taylor et al, 2006). In ARBITER 6-HALTS, addition of
niacin, but not addition of ezetimibe, reduced cIMT after
14 months in patients with CAD (or a CAD risk equivalent) and
an HDL-cholesterol level under 50mg (men)/55mg (women)
per deciliter, who were receiving long-term statin therapy and in
whom an LDL cholesterol level under 100mg per deciliter had
been achieved (Taylor et al, 2009).
The recently published Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High Triglycerides: Impact
on Global Health Outcomes trial (AIM-HIGH) included 3414
patients and addressed the question of whether addition of
1.5–2.0 g of ER-niacin per day would reduce the risk of major
cardiovascular events in patients with established cardiovas-
cular disease and atherogenic dyslipidemia (Boden, 2011). To
maintain an LDL cholesterol level of 40–80mg per deciliter, all
patients received simvastatin (40–80mg per day), plus ezeti-
mibe (10mg per day) if needed. The AIMHIGH trial was stopped
early after a mean follow-up of 3 years because niacin therapy
did not show any clinical benefit and there was an unexpected
higher number of ischemic strokes in patients randomized to
niacin. However, there are a number of limitations in this trial
that need to be taken into consideration. The trial was designed
with 85% power to show a 25% reduction in the primary
endpoint, which is clearly an overestimation in retrospect,
largely because of three reasons: first, the absolute difference in
HDL cholesterol levels between the niacin and placebo group
was small (i.e. 4–5mg/dl); second, the LDL cholesterol levels
were very low in both groups, 75% of patients in the placebo
group were on high-dose statin treatment and a further 20%
received ezetimibe as an add-on therapy to simvastatin; third,
there was a 25% discontinuation rate in the niacin group that
may have biased the results.
Furthermore, AIM-HIGH is the first trial to show a potential
association between niacin therapy and ischemic strokes. This
needs to be taken seriously and should be further examined in
future studies. However, there is no prior study or any biological
evidence suggesting that niacin might favour the occurrence of
ischemic strokes. The ongoing HPS-2-HRIVE trial examines ER-
niacin/laropiprant on-top of statin therapy in secondary
prevention, has included already more than 25,000 patients
and will therefore provide a more definite answer on the effects
of ER-niacin/laropiprant therapy on cardiovascular outcome
(NCT00461630).
CETP inhibitors
The interest in pharmacological CETP inhibition as novel
therapeutic approach to raise HDL cholesterol levels was
kindled by the finding of elevated HDL cholesterol levels in
Japanese families with genetic CETP deficiency. However, the
first compound tested in large clinical trials, torcetrapib, did not
to reduce the progression of carotid atheroslerosis in patients
with familial hypercholesterolemia receiving statin treatment
and was associated with progression of disease in the common
carotid segment (Kastelein et al, 2007). Of note, these effects
occurred despite a pronounced increase in HDL cholesterol
levels and a substantial decrease in LDL cholesterol and
trigylcerides (Kastelein et al, 2007).
More importantly, in the Investigation of Lipid Level
Management to Understand its Impact in Atherosclerotic Events
(ILLUMINATE) study, a large clinical outcome trial characteriz-
ing the effects of torcetrapib on major cardiovascular events in
patients at high cardiovascular risk who were receiving statins,
torcetrapib therapy was associated with an increased risk of
cardiovascular events and death from any cause (Barter et al,
2007b). This was, at least in part, due to an increase in blood
pressure, systemic aldosterone levels and alterations in serum
electrolytes related to ‘off-target’ effects of the compound on
aldosterone and cortisol synthesis in adrenal cortical cells
(Barter & Rye, 2011). Moreover, torcetrapib administration to
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spontaneously hypertensive rats impairs endothelial NO
production and increases production of reactive oxygen species
as well as endothelin-1 in the endothelium, leading to
endothelial dysfunction in these animals (Simic et al, 2011).
Three other CETP inhibitors are currently in clinical trials, i.e.
dalcetrapib, anacetrapib and evacetrapib. In contrast to
torcetrapib, none of these agents has been shown to alter
blood pressure, electrolytes or serum aldosterone.
In a 24h ambulatory blood pressure study, anacetrapib has
been shown to effectively raise HDL cholesterol levels in patients
with dyslipidemia after 4 weeks of therapy without affecting
blood pressure levels (Krishna et al, 2007). Comparable effects
were seen in 589 patients with hypercholesterolemia or mixed
hyperlipidemia and in this study, 8 weeks of anacetrapib
treatment led to an increase in HDL cholesterol by up to 139%
(Bloomfield et al, 2009). Of note, in this trial co-administration of
anacetrapib with atorvastatin resulted in significant incremental
LDL cholesterol reductions and similar HDL cholesterol increases
compared to atorvastatin therapy alone. In the recent DEFINE
trial, 1623 patients with coronary heart disease or at high risk for
coronary heart disease who were taking a statin and who had a
baseline LDL cholesterol level of 81mg/dl were assigned to
receive 100mg of anacetrapib or placebo daily for 18 months. As
compared to placebo, anacetrapib reduced LDL cholesterol levels
by 39.8% and resulted in 138% increase inHDL cholesterol levels
(Cannon et al, 2010). No changes were observed in blood
pressure, electrolyte or aldosterone levels and no increase in
adverse cardiovascular events was reported. The effects of
anacetrapib treatment on cardiovascular outcome will be
examined in the large global REVEAL HPS-3 TIMI-55 trial, which
will test whether anacetrapib reduces death and cardiovascular
morbidity in a population of approximately 30,000 patients with
cardiovascular disease.
Dalcetrapib has been shown to confer a more modest
inhibition of CETP activity and is currently evaluated in a large
clinical trial program of phase II and III studies. The recently
completed dal-VESSEL study has demonstrated no adverse
effects of dalcetrapib on arterial blood pressure or endothelial
function. The results of the dal-PLAQUE imaging trial that
characterized the effects of dalcetrapib or placebo treatment on
vessel wall structure (by MRI) and inflammation (by 18FDG-
PET/CT) for 24 months in patients with or without high risk of
CAD were recently published (Fayad et al, 2011). Importantly,
there was no evidence for an adverse effect of dalcetrapib on
structural parameters and inflammatory indices of the arterial
wall. At present, the dal-OUTCOMES trial is ongoing (and has
included approximately 15,600 patients) and will examine the
effects of dalcetrapib on cardiovascular outcome in patients
after a recent acute coronary syndrome.
Potential mechanisms underlying impaired HDL
functionality in patients with cardiovascular
disease
As described in more detail above, the capacity of HDL particles
of different size or structure to exert anti-atherogenic effects
differs. Changes in HDL functionality may have several causes,
including changes of the HDL proteome (protein composition or
modifications) and lipidome. Moreover, physicochemical
properties of the HDL particle can influence its anti-inflamma-
tory capacity, as the smaller and denser HDL3 subfraction has
been shown to be superior to the larger and less dense HDL2
subfraction in inhibiting TNF-a-induced VCAM-1 expression in
endothelial cells (Ashby et al, 1998).
Heterogeneity of the HDL proteome
Recent proteomics studies have identified between 28 and 67
HDL-associated proteins using liquid chromatography–electro-
spray ionization tandem mass spectrometry (LC-ESI-MS/MS)
(Davidson et al, 2009; Vaisar et al, 2007). Interestingly, these
proteomics studies of HDL have found not only proteins with
well-characterized roles in lipid metabolism and antioxidant
properties of HDL, but also a number of proteins involved in the
acute phase response, complement regulation and proteinase
inhibition. Of note, the protein composition of HDL may differ
between healthy subjects and patients with CAD (Vaisar et al,
2007), suggesting a potential remodelling of the HDL particle in
these patients. A combined statin and niacin therapy partially
reversed changes in the HDL proteome observed in patients with
CAD, yielding a protein composition that resembled that in
apparently healthy age- and sex-matched control subjects
(Green et al, 2008). However, whether changes in the HDL
proteome are of relevance for the altered vascular effects of HDL
in patients with CAD needs to be examined in future studies.
In addition, the protein composition of HDL changes during
acute inflammation as observed in mice after endotoxin
treatment or in humans after cardiac surgery (Chiba et al,
2011; Van Lenten et al, 1995). This has led to the term ‘acute
phase HDL’ that is characterized by an increase in serum
amyloid A (SAA), group IIa secretory phospholipase A2 (sPLA2-
IIa), and ceruloplasmin content, and a reduced apoA-I content.
Controversial data have been obtained for the cholesterol efflux
capacity of HDL during an acute phase response. While
McGillicuddy and coworkers observed an impaired macro-
phage-to-feces RCT during subacute endotoxemia in mice
(McGillicuddy et al, 2009), others observed a rather increased
ABCG-1 dependent cholesterol efflux capacity of HDL isolated
from mice during endotoxin challenge (de Beer et al, 2011), and
a preserved ABCA-1- and ABCG-1-dependent cholesterol efflux
capacity of HDL isolated from patients after cardiac surgery
(Jahangiri et al, 2009). However, the interpretation of these data
is complicated by the fact that SAA can itself act as an acceptor of
cellular cholesterol.
Posttranslational modifications of apoA-I
Oxidative modifications of apoA-I have been shown to impair
the cholesterol efflux capacity of HDL (Fig 4). In particular,
myeloperoxidase (MPO), a hypochlorous acid (HOCl)-generat-
ing enzyme that is enriched in human atheroma, can modify
apoA-I and induce chloro- and nitrotyrosine formation (Zheng
et al, 2004) as well as methionine oxidation (Shao et al, 2008).
Modification of HDL by MPO leads to a profound impairment of
the cholesterol efflux capacity of HDL (Bergt et al, 2004; Zheng
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et al, 2004) and an impaired capacity of HDL to stimulate
endothelial NO production (Sorrentino et al, 2010). Interest-
ingly, nitro-and chloro-tyrosine levels of apoA-I are higher in
patients with CAD as compared to healthy subjects (Zheng et al,
2004). However, there is an ongoing controversy about the
mechanisms whereby MPO modification renders apoA-I
dysfunctional.
Besides MPO-mediated oxidation, modification of HDL by
malondialdehyde, an advanced lipid oxidation product, has
been shown to impair the cholesterol efflux capacity of HDL in
vitro (Shao et al, 2010), suggesting that lipid oxidation itself can
induce alterations of HDL-associated proteins.
Characterization of the HDL lipidome
Considerably less is known about the HDL lipidome. It has been
demonstrated that HDL is enriched in phosphatidylcholine,
lysophosphatidylcholine, phosphatidylethanolamine and phos-
phatidylethanolamine-based plasmalogens, when compared to
other lipoprotein fractions in plasma (Wiesner et al, 2009).
However, a comprehensive and detailed profiling of the
molecular lipid species in HDL including information on the
type of fatty acids and the position where they are attached to
the glycerol backbone is not yet available. Furthermore, it
remains unknown whether the HDL-associated lipid profile
differs in patients with stable CAD or acute coronary syndrome.
Interestingly, it has been demonstrated that the phosphatidyl-
choline species composition of HDL influences its anti-
inflammatory activity (Baker et al, 2000), suggesting that the
lipid composition might be an important determinant of HDL
functionality. However, this needs to be tested in more detail in
future studies.
Role of PON1 for lipid oxidation and impaired endothelial-
protective effects of HDL in patients with CAD
PON1 is an HDL-associated esterase/lactonase that has been
shown to protect against lipid peroxide formation in LDL
and HDL. Notably, we have recently shown that the activity
of HDL-associated PON1 was profoundly impaired in HDL
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from patients with CAD as compared to HDL from age-
and gender-matched healthy subjects (Besler et al, 2011).
Inhibition of HDL-associated PON1, as observed in patients with
CAD, led to an increase of MDA-lysine adducts in HDL that
subsequently activated endothelial protein kinase C beta II
(PKCbII) via the endothelial LOX-1 receptor (Fig 4). In turn,
stimulation of endothelial PKCbII by HDL from patients with
CAD led to an inhibition of signalling pathways that are
necessary for activation of eNOS, i.e. phosphorylation of eNOS
at serine residue 1177 and dephosphorylation of eNOS at
threonine residue 495. Compatible with the concept that
activation of endothelial PKCbII limits eNOS stimulation by
HDL from patients with CAD, inhibition of endothelial
PKCbII partially restored the impaired capacity of HDL from
patients with CAD to increase endothelial NO production
(Besler et al, 2011).
Conclusion
Low plasma levels of HDL cholesterol are associated with an
increased risk of coronary disease and myocardial infarction.
HDL is considered an anti-atherogenic lipoprotein, largely
based on experimental studies suggesting several potential
anti-atherogenic properties of HDL. At the same time it has
become clear that the biological functions of HDL, i.e.
endothelial-atheroprotective effects, are highly heterogenous
and are altered in patients with coronary disease or diabetes.
These observations may have profound implications for
the understanding of the vascular effects of HDL-targeted or
HDL-raising therapies. Indeed, the simple notion that
raising plasma HDL cholesterol levels by itself will always
translate into a reduction of atherosclerotic vascular disease can
no longer be sustained, because HDL cholesterol levels alone
represent an insufficient measure of the antiatherogenic
capacity of HDL.
Therefore reliable and validated assays of HDL functionality
are needed to better assess the therapeutic effects of HDL-
targeted therapeutic interventions on vasoprotective effects of
HDL. In this respect, an important open question in the field
remains which alterations of the atheroprotective functions of
HDL are related to adverse clinical cardiovascular outcome in
patients with CAD. It is at present unknown which potential
atheroprotective function of HDL, or which particular protein or
lipid marker in HDL, may be suited best to assess the
antiatherogenic capacity of HDL. It seems likely that only
raising HDL with vasoprotective properties can be expected to
exert beneficial cardiovascular effects. In addition, the mole-
cular target leading to increased HDL cholesterol levels will
represent a critical determinant for the vascular effects of HDL-
raising therapeutic interventions, and should likely not involve
mechanisms that hinder vasoprotective functions of HDL (such
as blockade of the SR-BI receptor).
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